Sagimet Biosciences to Participate in the Piper Sandler 36th Annual Healthcare Conference
Sagimet Biosciences to Participate in the Piper Sandler 36th Annual Healthcare Conference
Sagimet is a clinical-stage biopharmaceutical company developing novel fatty acid synthase (FASN) inhibitors that are designed to target dysfunctional metabolic and fibrotic pathways in diseases resulting from the overproduction of the fatty acid, palmitate. Sagimet's lead drug candidate, denifanstat, is an oral, once-daily pill and selective FASN inhibitor in development for the treatment of metabolic dysfunction associated steatohepatitis (MASH). FASCINATE-2, a Phase 2b clinical trial of denifanstat in MASH with liver biopsy-based primary endpoints, was successfully completed with positive results. Denifanstat has been granted Breakthrough Therapy designation by the FDA for the treatment of non-cirrhotic MASH with moderate to advanced liver fibrosis (consistent with stages F2 to F3 fibrosis), and end-of-Phase 2 interactions with the FDA have been successfully completed, supporting the advancement of denifanstat into Phase 3 development in MASH. For additional information about Sagimet, please visit .SAN MATEO, Calif., Nov. 26, 2024 (GLOBE NEWSWIRE) -- Sagimet Biosciences Inc. (Sagimet, Nasdaq: SGMT), a clinical-stage biopharmaceutical company developing novel therapeutics targeting dysfunctional metabolic and fibrotic pathways, today announced that management will present at the Piper Sandler 36th Annual Healthcare Conference on Tuesday, December 3, 2024 at 10 a.m. EST in New York City, New York.
加利福尼亞州聖馬特奧，2024年11月26日（環球新聞社）-- Sagimet生物科學公司（Sagimet，納斯達克：SGMT），一家處於臨床階段的生物製藥公司，致力於開發針對代謝和纖維化通路功能異常的新型治療藥物，今天宣佈管理層將於2024年12月3日星期二美國東部時間上午10點在紐約市的派傑投資第36屆醫療保健年會上發言。
A webcast of the presentation will be available in the Investors & Media section of Sagimet's website at , with an archived replay available for 90 days following the live event.
演示的網絡廣播將在Sagimet網站的投資者與媒體欄目中提供，現場活動結束後的90天內可提供存檔回放。
About Sagimet Biosciences
關於世紀醫藥公司
Sagimet is a clinical-stage biopharmaceutical company developing novel fatty acid synthase (FASN) inhibitors that are designed to target dysfunctional metabolic and fibrotic pathways in diseases resulting from the overproduction of the fatty acid, palmitate. Sagimet's lead drug candidate, denifanstat, is an oral, once-daily pill and selective FASN inhibitor in development for the treatment of metabolic dysfunction associated steatohepatitis (MASH). FASCINATE-2, a Phase 2b clinical trial of denifanstat in MASH with liver biopsy-based primary endpoints, was successfully completed with positive results. Denifanstat has been granted Breakthrough Therapy designation by the FDA for the treatment of non-cirrhotic MASH with moderate to advanced liver fibrosis (consistent with stages F2 to F3 fibrosis), and end-of-Phase 2 interactions with the FDA have been successfully completed, supporting the advancement of denifanstat into Phase 3 development in MASH. For additional information about Sagimet, please visit .
Sagimet是一家臨床階段的生物製藥公司，正在開發新型脂肪酸合成酶（FASN）抑制劑，旨在針對由多餘合成脂肪酸棕櫚酸所致的疾病中的代謝和纖維化通路。Sagimet的首席候選藥物Denifanstat是一種口服、每日一次的藥丸，是一種選擇性FASN抑制劑，用於治療與代謝紊亂相關的類脂肪肝（MASH）。基於肝活檢的主要終點的FASCINATE-2，Denifanstat在MASH中進行的第20億期臨床試驗以積極結果成功完成。Denifanstat已獲得FDA授予突破性療法指定，用於治療具有中度到重度肝纖維化（與F2至F3纖維化階段一致）的非肝硬化MASH，與FDA的第2階段最終階段互動已經成功完成，支持Denifanstat進入MASH的第3期發展。有關Sagimet的更多信息，請訪問。
Contact:
Joyce Allaire
LifeSci Advisors
jallaire@lifesciadvisors.com
聯繫方式：
Joyce Allaire
生命科學顧問
jallaire@lifesciadvisors.com
Source: Sagimet Biosciences Inc.
來源：Sagimet生命科學公司。
譯文內容由第三人軟體翻譯。
